middl
east
respiratori
syndrom
mer
viral
respiratori
diseas
caus
mer
coronaviru
rel
new
first
report
took
place
saudi
arabia
afterward
mer
case
report
across
wide
geograph
distribut
around
globe
howev
vast
major
case
directli
indirectli
link
travel
resid
middl
vaccin
current
recommend
advis
peopl
adher
gener
prevent
measur
handwash
frequent
disinfect
touch
surfac
avoid
person
contact
infect
clinic
pictur
infect
rang
asymptomat
mild
respiratori
symptom
sever
acut
respiratori
diseas
infect
patient
present
symptom
cough
short
breath
fever
chill
rapidli
progress
sever
ill
pneumonia
acut
respiratori
distress
symptom
mani
requir
mechan
ventil
furthermor
mer
complic
acut
renal
failur
requir
hemodialysi
dissemin
intravascular
coagul
multiorgan
failur
contribut
high
mortal
current
reliabl
remedi
mer
intervent
rang
support
antivir
therapi
two
vitro
studi
suggest
possibl
efficaci
effect
interferon
ribavirin
treatment
mer
consequ
investig
examin
efficaci
drug
anim
potenti
benefit
antivir
treatment
vitro
anim
studi
persuad
clinician
question
feasibl
applic
approach
human
therefor
aim
recapitul
evid
human
publish
data
mer
clinic
manag
systemat
review
summar
efficaci
safeti
current
appli
therapeut
defin
risk
factor
associ
outcom
result
may
provid
better
approach
compat
manag
fatal
consequ
mer
infect
risk
impos
recent
outbreak
dens
popul
area
studi
perform
accord
recommend
prefer
report
item
systemat
review
develop
protocol
method
regist
intern
prospect
regist
systemat
review
prospero
refer
june
conduct
systemat
search
databas
includ
pubm
scopu
web
scienc
googl
scholar
global
health
librari
virtual
health
librari
contain
cochran
medlin
lilac
ibec
scielo
poplin
new
york
academi
medicin
grey
literatur
report
nyamglr
sigl
clinicaltrialsgov
search
result
limit
refer
publish
sinc
januari
mer
first
detect
addit
human
filter
appli
case
pubm
remov
duplic
three
train
review
assign
independ
screen
titl
abstract
refer
gener
aforement
search
strategi
basi
follow
inclus
exclus
criteria
inclus
criteria
studi
give
inform
treatment
infect
b
type
studi
design
includ
c
restrict
made
respect
languag
age
area
exclus
criteria
data
could
reliabl
extract
b
data
set
consid
overlap
c
studi
publish
book
chapter
thesi
letter
confer
paper
poster
editori
e
anim
vitro
studi
three
review
compar
screen
result
discuss
differ
consensu
reach
discuss
extract
data
includ
public
year
year
research
countri
citi
patient
year
subject
recruit
studi
design
particip
enrol
data
collect
method
baselin
characterist
treatment
diagnost
method
time
admiss
treatment
start
treatment
outcom
surviv
work
conduct
investig
evalu
refer
independ
disagr
discuss
reach
consensu
supervisor
qualiti
includ
clinic
data
assess
use
care
statement
case
metric
tool
nonrandom
three
review
assign
assess
includ
refer
independ
mortal
rate
treat
dichotom
variabl
respect
confidenti
interv
ci
statist
heterogen
assess
use
assum
influenti
greater
p
model
use
evid
heterogen
studi
perform
use
data
analysi
statist
softwar
stata
develop
statacorp
fisher
exact
appropri
u
test
use
categor
continu
variabl
respect
classif
regress
tree
cart
model
use
identifi
independ
variabl
predict
mortal
invas
ventil
renal
replac
therapi
also
chosen
outcom
cart
model
direct
correl
sever
possibl
variabl
extract
build
cart
tabl
found
support
inform
perform
paramet
accuraci
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
result
consid
statist
signific
p
valu
evalu
surviv
rate
time
group
ifn
treatment
test
surviv
analysi
perform
perform
set
surviv
curv
first
set
describ
surviv
time
hospit
admiss
death
second
set
report
surviv
time
onset
symptom
death
mean
surviv
day
calcul
set
patient
still
admiss
origin
studi
end
includ
curv
consid
expir
patient
final
analysi
data
analyz
use
statist
comput
graphic
r
softwar
version
develop
r
foundat
statist
comput
statist
packag
social
scienc
spss
releas
intern
busi
machin
corpor
use
analysi
well
total
refer
retriev
upon
screen
regard
inclus
exclus
criteria
section
eleven
refer
includ
data
extract
addit
refer
identifi
manual
total
studi
elig
select
shown
figur
studi
includ
patient
case
case
observ
saudi
arabia
countri
origin
patient
studi
rest
franc
greec
qatar
detail
characterist
patient
includ
articl
present
tabl
eight
studi
use
specif
antivir
studi
use
support
treatment
includ
invas
ventil
prone
posit
renal
replac
therapi
vasopressor
corticosteroid
immunoglobulin
oseltamivir
omrani
et
use
specif
antivir
treatment
support
treatment
specif
antivir
treatment
ifn
ribavirin
sever
other
includ
tenofovir
emtricitabin
lopinavir
ritonavir
among
patient
recruit
report
detail
inform
regard
baselin
characterist
comorbid
treatment
outcom
surviv
time
subsequ
use
perform
univari
analysi
surviv
curv
tabl
found
support
inform
hemodialysi
depend
appear
higher
frequenc
ifn
group
group
p
convers
renal
replac
therapi
vasopressor
use
often
group
ifn
group
p
tabl
qualiti
case
case
assess
use
care
checklist
tabl
found
support
inform
contain
introduct
describ
import
case
abstract
main
introduct
section
demograph
symptom
patient
signific
clinic
find
timelin
patient
histori
organ
diagnost
method
type
treatment
clinic
outcom
discuss
relev
medic
literatur
rational
conclus
primari
take
away
lesson
case
report
howev
none
describ
diagnost
challeng
prognost
characterist
patient
perspect
gueri
et
report
obtain
inform
consent
patient
qualiti
observ
assess
use
metric
tabl
found
support
inform
three
describ
studi
design
characterist
patient
popul
inclus
criteria
method
qualiti
mer
diagnosi
howev
none
studi
describ
data
collect
method
assign
method
patient
exclus
criteria
interpret
treatment
antivir
drug
oseltamivir
report
studi
ifn
ifn
combin
ribavirin
common
remedi
use
studi
ifn
use
studi
n
patient
use
dose
treatment
ifn
use
studi
n
dose
rang
ifn
dose
report
et
ifn
use
studi
n
use
dose
ribavirin
administr
start
load
dose
follow
subsequ
dose
studi
load
dose
mg
studi
mg
one
studi
alghamdi
et
subsequ
dose
howev
variabl
among
studi
rang
mgd
frequenc
administr
ribavirin
dose
per
day
dose
per
day
anoth
durat
treatment
ribavirin
also
variabl
rang
day
subsequ
oral
ribavirin
dose
adjust
accord
calcul
creatinin
clearanc
howev
durat
treatment
day
load
dose
mg
use
studi
similar
regardless
creatinin
clearanc
tabl
found
support
inform
addit
treatment
ifn
ribavirin
treatment
regimen
shalhoub
et
includ
treatment
tenofoviremtricitabin
tdfftc
mg
oral
daili
combin
atazanavir
atazanavir
mg
plu
ritonavir
mg
oral
daili
similarli
tripl
therapi
ifn
ribavirin
lopinavirritonavir
mg
twice
daili
use
treat
greek
patient
spanaki
et
worth
mention
signific
lag
period
present
initi
antivir
treatment
period
admiss
patient
initi
antivir
ifn
ribavirin
report
patient
mean
day
rang
day
khalid
et
day
et
al
tabl
found
support
inform
support
treatment
alon
use
studi
n
patient
wherea
support
treatment
along
antivir
medic
use
anoth
studi
n
one
studi
compar
supportiveantivir
medic
support
treatment
alon
n
respect
differ
modal
treatment
use
support
patient
includ
invas
ventil
extracorpor
membran
oxygen
corticosteroid
renal
replac
therapi
vasopressor
oseltamivir
prone
posit
patient
requir
use
invas
mechan
ventil
patient
ifn
treatment
group
compar
patient
support
group
regard
mortal
studi
case
includ
pool
proport
mortal
studi
includ
mer
patient
figur
patient
receiv
ifn
treatment
mortal
rate
high
spite
receiv
treatment
ribavirin
plu
ifn
likewis
mortal
rate
high
patient
receiv
support
treatment
n
statist
signific
mortal
differ
compar
mortal
group
p
tabl
insignific
mortal
differ
shown
compar
type
ifn
treatment
ifn
ifn
ifn
p
tabl
durat
hospit
death
report
deceas
patient
report
patient
die
within
month
hospit
moreov
patient
die
within
first
week
admiss
die
within
month
admiss
case
seri
patient
saudi
arabia
khalid
et
patient
comorbid
condit
need
mechan
ventil
die
patient
requir
mechan
ventil
surviv
case
report
greec
describ
one
patient
infect
die
despit
receiv
ifn
ribavirin
lopinavir
patient
multiorgan
failur
later
diagnos
colon
cancer
detect
respiratori
tract
sever
day
regard
advers
effect
interferon
ribavirin
combin
therapi
patient
pancreat
enzym
elev
one
signific
hemolysi
treat
ifn
plu
addit
reduct
hemoglobin
level
gl
mer
patient
treat
ifn
plu
ribavirin
wherea
omrani
et
report
gl
hemoglobin
reduct
patient
treat
treatment
p
signific
differ
death
surviv
patient
chronic
renal
diseas
crd
nine
crd
patient
die
deceas
case
patient
crd
surviv
group
addit
diabet
mellitu
dm
hypertens
show
similar
signific
variat
suggest
crd
hypertens
andor
dm
increas
risk
mortal
p
signific
differ
death
surviv
regard
gender
ribavirin
corticosteroid
oseltamivir
ifn
ifn
ifn
congest
heart
failur
comorbid
p
deceas
patient
requir
mechan
ventil
die
compar
patient
surviv
patient
p
continu
variabl
signific
differ
death
surviv
age
dead
patient
older
time
onset
ill
initi
antivir
treatment
longer
deceas
patient
p
tabl
model
tool
cart
identifi
crd
best
paramet
predict
mortal
figur
perform
decis
tree
tool
classifi
mortal
outcom
accuraci
sensit
specif
ppv
npv
addit
treatment
inotrop
exhibit
best
paramet
predict
renal
replac
therapi
outcom
figur
perform
decis
tree
tool
classifi
renal
replac
therapi
outcom
accuraci
sensit
specif
ppv
npv
signific
result
detect
regard
invas
ventil
outcom
surviv
time
admiss
death
compar
n
support
care
n
patient
case
die
within
day
hospit
admiss
figur
one
femal
case
treat
ifn
elimin
analysi
patient
remain
intub
origin
studi
end
howev
met
death
criteria
thu
includ
deceas
patient
final
outcom
analysi
mean
surviv
day
day
ci
ifn
group
day
ci
group
p
overal
mean
surviv
day
group
ci
case
ifn
group
case
group
report
inform
time
onset
symptom
death
second
surviv
analysi
perform
show
die
within
day
onset
ill
mean
surviv
day
ci
ifn
group
compar
ci
group
differ
group
statist
signific
p
figur
longer
surviv
period
onset
death
simpli
attribut
durat
onset
admiss
mean
time
onset
ill
admiss
patient
ifn
group
day
compar
number
patient
group
mean
day
mean
differ
md
time
group
also
calcul
md
ci
p
specif
comparison
death
versu
nondeath
case
ifn
support
treatment
conduct
get
mean
day
onset
admiss
mean
day
dead
patient
surviv
respect
md
ci
p
moreov
mean
day
support
treat
dead
patient
support
treat
surviv
respect
md
ci
p
mean
day
onset
ill
admiss
pool
total
case
death
surviv
respect
md
ci
p
systemat
review
highlight
signific
age
period
ill
onset
start
antivir
therapi
mer
case
prognost
assess
result
reveal
younger
age
rapid
initi
antivir
therapi
associ
higher
chanc
surviv
also
found
patient
requir
ventil
like
die
compar
patient
requir
furthermor
differ
ifn
treatment
support
treatment
term
mortal
rate
signific
effect
durat
surviv
infect
patient
differ
group
sever
factor
affect
clinic
outcom
mer
therapi
data
significantli
higher
number
patient
hypertens
dialysi
depend
ifn
group
compar
group
surviv
time
patient
receiv
antivir
therapi
efficaci
drug
like
reduc
hypertens
dialysi
depend
nevertheless
upon
investig
outcom
patient
treatment
mer
found
despit
higher
number
comorbid
ifn
group
compar
group
patient
ifn
surviv
consider
longer
onset
symptom
support
therapi
result
highlight
potenti
efficaci
antivir
treatment
infect
howev
number
case
small
draw
conclus
studi
definit
requir
term
differ
support
remedi
corticosteroid
show
promis
effect
surviv
infect
patient
also
consist
previou
patient
sign
sever
respiratori
distress
shock
hypoxemia
given
oxygen
therapi
immedi
maintain
oxygen
therapi
consid
intub
mechan
ventil
howev
noninvas
ventil
avoid
high
risk
spread
patient
indic
ventil
like
accompani
seriou
condit
compar
could
explain
higher
risk
mortal
among
patient
shown
result
high
case
fatal
rate
faster
progress
respiratori
failur
press
distinguish
mer
sever
acut
respiratori
syndrom
time
manag
howev
consid
diagnost
challeng
health
care
profession
due
similar
clinic
result
obtain
cart
model
suggest
chronic
respiratori
diseas
best
predictor
death
patient
mer
therefor
utmost
necess
thoroughli
assess
continu
monitor
respiratori
function
patient
suspect
infect
also
health
care
agenc
high
risk
area
recommend
bridg
gap
medic
facil
personnel
get
staff
familiar
precauti
measur
requir
face
futur
outbreak
studi
limit
small
number
includ
articl
patient
hinder
abil
valid
cart
model
addit
publish
clinic
trial
even
one
ongo
clinic
trial
found
test
combin
lopinavirritonavir
ifn
therapi
mer
patient
anoth
recent
trial
regist
yet
start
recruit
investig
safeti
immunogen
vaccin
nevertheless
investig
requir
object
assess
effect
antivir
therapi
surviv
durat
overal
outcom
infect
evid
differ
ifn
treatment
support
treatment
mer
patient
term
mortal
ribavirin
ifn
combin
might
promis
effect
therapi
start
promptli
advers
effect
monitor
care
random
control
trial
requir
assess
possibl
concern
prognost
factor
delay
treatment
older
age
accompani
comorbid
hypertens
dm
chronic
kidney
diseas
dialysi
depend
associ
wors
outcom
high
fatal
serious
newli
emerg
diseas
limit
number
avail
case
believ
urgent
need
clinic
trial
efficaci
antivir
treatment
infect
author
declar
compet
interest
work
support
part
scientif
research
b
nguyen
tien
huy
ministri
educ
cultur
sport
scienc
technolog
mext
japan
japan
initi
global
research
network
infecti
diseas
kenji
hirayama
funder
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
nth
aag
mem
kh
particip
design
studi
lvt
lmd
mgk
nlv
amaa
perform
analysi
interpret
author
contribut
screen
data
extract
wrote
manuscript
read
approv
final
manuscript
